PDRX: AI 评分 44/100 — AI 分析 (4月 2026)

PD-Rx Pharmaceuticals, Inc. focuses on repackaging and distributing prepackaged pharmaceutical products to healthcare providers in the United States. The company offers a range of medications, dispensing systems, and support services to physicians, pharmacies, and medical clinics.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

PD-Rx Pharmaceuticals, Inc., established in 1986, operates within the medical distribution sector, providing prepackaged medications and dispensing solutions to healthcare providers across the United States. The company's offerings include a variety of medications, web-based prescription tracking, and pharmaceutical sampling programs, serving physicians, pharmacies, and medical clinics.

PDRX是做什么的？

PD-Rx Pharmaceuticals, Inc., founded in 1986 and headquartered in Oklahoma City, Oklahoma, operates within the healthcare industry, specializing in the repackaging and distribution of prepackaged pharmaceutical products. The company serves a diverse clientele, including physicians, pharmacies, and medical clinics throughout the United States. PD-Rx Pharmaceuticals offers a comprehensive portfolio of approximately 2,600 prepackaged medications, encompassing creams, ointments, ophthalmics, otics, liquids, and suspensions. Beyond its distribution capabilities, PD-Rx Pharmaceuticals provides technological solutions to streamline prescription management. PD-Rx Net, a web-based application, enables healthcare providers to track prescriptions filled at the point of care and print prescription labels for onsite dispensing. Additionally, the company offers a manual dispensing system, complete with recordkeeping labels, designed for physician dispensing customers. PD-Rx Pharmaceuticals also distinguishes itself through its commitment to customer support and cost-effectiveness. The company provides professional assistance from staffed pharmacists and physicians, ensuring that clients receive expert guidance and support. Furthermore, PD-Rx Pharmaceuticals designs pharmaceutical sampling programs aimed at reducing pharmaceutical costs for Managed Care Organizations (MCOs), while also enabling medical professionals to offer pre-filled prescriptions to patients free of charge.

PDRX的投资论点是什么？

PD-Rx Pharmaceuticals, Inc. operates in the niche market of prepackaged pharmaceutical distribution, offering convenience to healthcare providers. However, the company's negative profit margin of -1.4% and a P/E ratio of -19.98 indicate financial challenges. The beta of -1366978.48 suggests an inverse correlation with the market, which can be both a risk and an opportunity. Growth catalysts include expanding its PD-Rx Net platform and pharmaceutical sampling programs. The company's ability to achieve profitability and manage its cost structure will be critical for long-term success. Investors should closely monitor its financial performance and competitive positioning within the medical distribution sector.

PDRX在哪个行业运营？

PD-Rx Pharmaceuticals, Inc. operates within the medical distribution industry, which is characterized by increasing demand for efficient pharmaceutical supply chains and point-of-care dispensing solutions. The industry is influenced by factors such as regulatory changes, technological advancements, and the growing emphasis on cost containment within the healthcare system. Competitors like CPIVF, FZMD, IDXG, KOSK, and MVMDF operate in similar spaces, providing various pharmaceutical products and services. PD-Rx Pharmaceuticals differentiates itself through its focus on prepackaged medications and its PD-Rx Net platform.

Medical - Distribution

Healthcare

PDRX有哪些增长机遇？

Expansion of PD-Rx Net Platform: The company can focus on enhancing and expanding its PD-Rx Net platform, a web-based application that tracks prescriptions filled at the point of care. By adding more features and integrations, PD-Rx can attract more physicians and pharmacies, increasing its market share. The market for healthcare IT solutions is projected to reach $390 billion by 2027, offering a significant growth opportunity.
Pharmaceutical Sampling Program Design: PD-Rx Pharmaceuticals can further develop its pharmaceutical sampling program design to reduce pharmaceutical costs for MCOs. This program allows medical professionals to offer pre-filled prescriptions to patients free of charge. As healthcare costs continue to rise, MCOs are actively seeking cost-saving solutions, making this a viable growth area. The pharmaceutical sampling market is estimated to be worth $20 billion annually.
Strategic Partnerships with Medical Clinics: Forming strategic partnerships with medical clinics to provide prepackaged medications and dispensing solutions can drive revenue growth. By offering a comprehensive suite of services, PD-Rx can become an integral part of the clinic's operations, ensuring a steady stream of orders. The number of medical clinics is growing at a rate of 3% annually, presenting a large potential market.
Geographic Expansion: Expanding its operations to new geographic regions within the United States can significantly increase PD-Rx's customer base. By targeting states with a high concentration of physicians and pharmacies, the company can capitalize on untapped markets. The US pharmaceutical market is the largest in the world, with a value of over $500 billion, offering ample opportunities for growth.
Development of Specialty Medication Packaging: Focusing on the development of specialized packaging solutions for specialty medications can cater to a growing niche market. Specialty medications often require specific handling and storage conditions, creating a demand for specialized packaging. The specialty pharmaceutical market is growing at a rate of 8% annually, driven by the increasing prevalence of chronic diseases and the development of innovative therapies.

Market capitalization of $0.01 billion indicates a small-cap company.
Negative P/E ratio of -19.98 suggests the company is currently not profitable.
Profit margin of -1.4% reflects operational inefficiencies or pricing pressures.
Beta of -1366978.48 indicates an inverse correlation with the market, suggesting the stock may move opposite to market trends.
No dividend yield, indicating the company is not currently returning profits to shareholders.

PDRX提供哪些产品和服务？

Repackages and distributes prepackaged pharmaceutical products.
Provides approximately 2,600 prepackaged medications.
Offers creams, ointments, ophthalmics, otics, liquids, and suspensions.
Provides PD-Rx Net, a web-based application for prescription tracking.
Offers a manual dispensing system with recordkeeping labels.
Provides professional assistance from staffed pharmacists and physicians.
Designs pharmaceutical sampling programs to reduce MCO's pharmaceutical costs.

PDRX如何赚钱？

Generates revenue through the sale of prepackaged medications to physicians, pharmacies, and medical clinics.
Offers PD-Rx Net subscription for prescription tracking and label printing.
Provides pharmaceutical sampling program design services to MCOs.
Offers manual dispensing systems and related supplies.

Physicians
Pharmacies
Medical Clinics

Established relationships with physicians, pharmacies, and medical clinics.
Proprietary PD-Rx Net web-based application for prescription tracking.
Specialized expertise in repackaging and distributing prepackaged medications.
Pharmaceutical sampling program design capabilities.

什么因素可能推动PDRX股价上涨？

Ongoing: Expansion of PD-Rx Net platform to attract more customers and increase subscription revenue.
Ongoing: Strategic partnerships with medical clinics to drive sales and expand market reach.
Upcoming: Potential regulatory changes in the pharmaceutical industry that could benefit smaller distributors.
Ongoing: Development of new pharmaceutical sampling programs to reduce costs for MCOs.
Ongoing: Geographic expansion to new regions within the United States to tap into untapped markets.

PDRX的主要风险是什么？

Ongoing: Intense competition from larger pharmaceutical distributors with greater resources.
Potential: Economic downturn affecting healthcare spending and reducing demand for pharmaceutical products.
Potential: Regulatory changes impacting the pharmaceutical industry and increasing compliance costs.
Potential: Product liability claims arising from the distribution of pharmaceutical products.
Ongoing: The company's financial instability, with a negative profit margin and P/E ratio.

PDRX的核心优势是什么？

Established presence in the prepackaged pharmaceutical distribution market.
Proprietary PD-Rx Net platform for prescription tracking.
Comprehensive range of prepackaged medications.
Pharmaceutical sampling program design expertise.

PDRX的劣势是什么？

Negative profit margin indicates financial instability.
Small market capitalization limits access to capital.
High beta suggests significant volatility.
Dependence on a niche market segment.

PDRX有哪些机遇？

Expansion of PD-Rx Net platform to attract more customers.
Strategic partnerships with medical clinics to increase sales.
Geographic expansion to new regions within the United States.
Development of specialty medication packaging solutions.

PDRX面临哪些威胁？

Increasing competition from larger pharmaceutical distributors.
Regulatory changes impacting the pharmaceutical industry.
Economic downturn affecting healthcare spending.
Potential for product liability claims.

PDRX的竞争对手是谁？

Cann Pharmaceutical Israel Ltd — Focuses on cannabis-based pharmaceutical products. — (CPIVF)
Pharma-Medical Science Inc. — Develops and markets pharmaceutical and medical products. — (FZMD)
Interpace Biosciences, Inc. — Provides molecular diagnostic tests for cancer. — (IDXG)
KOSDAQ — South Korean stock market; not a direct competitor but represents the broader market. — (KOSK)
Medivolve Inc. — Focuses on telehealth and point-of-care testing. — (MVMDF)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Robert D. Holsey
Headquarters: Oklahoma City, US
Founded: 2003

AI Insight

AI analysis pending for PDRX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does PD-Rx Pharmaceuticals, Inc. do?

PD-Rx Pharmaceuticals, Inc. specializes in the repackaging and distribution of prepackaged pharmaceutical products to healthcare providers across the United States. The company offers a diverse range of approximately 2,600 prepackaged medications, including creams, ointments, ophthalmics, otics, liquids, and suspensions. In addition to its distribution services, PD-Rx Pharmaceuticals provides technological solutions such as the PD-Rx Net platform, which enables healthcare providers to track prescriptions and print labels. The company also designs pharmaceutical sampling programs to reduce costs for Managed Care Organizations (MCOs).

What do analysts say about PDRX stock?

As of March 16, 2026, formal analyst ratings for PD-Rx Pharmaceuticals, Inc. (PDRX) are not widely available, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio and profit margin, suggest financial challenges. Growth considerations revolve around the company's ability to expand its PD-Rx Net platform, form strategic partnerships, and manage its cost structure. Investors should conduct their own thorough research and consider the risks associated with investing in OTC stocks.

What are the main risks for PDRX?

The main risks for PD-Rx Pharmaceuticals, Inc. include intense competition from larger pharmaceutical distributors, regulatory changes impacting the pharmaceutical industry, and economic downturns affecting healthcare spending. The company's financial instability, with a negative profit margin and P/E ratio, also poses a significant risk. Additionally, its listing on the OTC Other tier carries increased risks due to limited financial disclosure, low trading volume, and a lack of regulatory oversight. Investors should carefully consider these risks before investing in PDRX.